Comprehensive analysis of HFE gene in hereditary hemochromatosis and in diseases associated with acquired iron overload
Carregando...
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2019
Título da Revista
ISSN da Revista
Título do Volume
Editora
BAISHIDENG PUBLISHING GROUP INC
Autores
CAMPOS, Wagner Narciso de
MASSARO, Juliana Doblas
WIEZEL, Claudia Emilia Vieira
SIMOES, Aguinaldo Luiz
TEIXEIRA, Andreza Correa
SOUZA, Fernanda Fernandes de
MENDES-JUNIOR, Celso Teixeira
MARTINELLI, Ana de Lourdes Candolo
DONADI, Eduardo Antonio
Citação
WORLD JOURNAL OF HEPATOLOGY, v.11, n.2, p.186-198, 2019
Resumo
BACKGROUND Patients with hepatitis C virus (HCV) and hepatocellular carcinoma (HCC) may or not develop iron overload (IO), which is associated with worst prognosis, because can cause serious damage to organs. HFE gene controls the iron uptake from gut, particularly in patients with hereditary hemochromatosis (HH). AIM To identify associations between HFE coding region in patients exhibiting hereditary hemochromatosis and in diseases associated with acquired IO. METHODS We sequenced exons 2 to 5 and boundary introns of HFE gene, evaluating all polymorphic sites in patients presenting hereditary (hemochromatosis) or acquired iron overload HCV and HCC) and in healthy controls, using Sanger sequencing. We also determined the ensemble of extended haplotype in healthy control individuals, including several major histocompatibility complex loci, using sequence specific probes. Haplotype reconstruction was performed using the Arlequin and Phase softwares, and linkage disequilibrium (LD) between histocompatibility loci and HFE gene was performed using the Haploview software. RESULTS The HFE* 003 allele was overrepresented (f = 71%) and HFE* 001 allele was underrepresented (f = 14%) in HH patients compared to all groups. A strong linkage disequilibrium was observed among the H63D-G, IVS2(+ 4)-C and C282YG gene variants, particularly in HH; however, the mutation IVS2(+ 4) T>C was not directly associated with HH susceptibility. The HFE* 001/HFE* 002 genotype conferred susceptibility to HCC in HCV patients exhibiting IO (P = 0.02, OR = 14.14). Although HFE is telomeric to other histocompatibility genes, the H63DG/ IVS2(+ 4)-C (P = 0.00001/P = 0.0057) combination was in LD with HLA-B* 44 allele group in healthy controls. No LD was observed between HFE alleles and other major histocompatibility loci. CONCLUSION A differential HFE association was observed for HH and for diseases associated with acquired IO (HCV, HCC). Since HFE is very distant from other histocompatibility loci, only weak associations were observed with these alleles.
Palavras-chave
HFE gene, Hepatocellular carcinoma, Hepatitis C, Hemochromatosis hereditary, Alleles, Haplotypes
Referências
- Anderson GJ, 2004, J GASTROEN HEPATOL, V19, P712, DOI 10.1111/j.0815-9319.2004.03499.x
- ArnaizVillena A, 1997, IMMUNOGENETICS, V47, P37, DOI 10.1007/s002510050324
- Barton James C, 2002, BMC Med Genet, V3, P9, DOI 10.1186/1471-2350-3-9
- Boige V, 2003, GUT, V52, P1178, DOI 10.1136/gut.52.8.1178
- Bonkovsky HL, 2002, J HEPATOL, V37, P848, DOI 10.1016/S0168-8278(02)00305-7
- BRISSOT P, 1981, GASTROENTEROLOGY, V80, P557
- Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199
- Bueno Simone, 2006, Rev. Bras. Hematol. Hemoter., V28, P293, DOI 10.1590/S1516-84842006000400015
- Campos WN, 2017, HLA, V90, P238, DOI 10.1111/tan.13097
- Cançado Rodolfo D., 2007, Rev. Bras. Hematol. Hemoter., V29, P351, DOI 10.1590/S1516-84842007000400007
- Cançado Rodolfo Delfini, 2006, Sao Paulo Med. J., V124, P55, DOI 10.1590/S1516-31802006000200002
- Cardoso CS, 2003, TISSUE ANTIGENS, V61, P263, DOI 10.1034/j.1399-0039.2003.00065.x
- Castelli EC, 2010, GENES IMMUN, V11, P134, DOI 10.1038/gene.2009.74
- de Lima Santos PC, 2010, HEMOCROMATOSE HEREDI, DOI [10.11606/T.9.2011.tde-04022011-110402, DOI 10.11606/T.9.2011.TDE-04022011-110402]
- de Lucas AP, 2005, GENET MED, V7, P212, DOI 10.1097/01.GIM.0000157125.89581.09
- DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1016/0270-9139(94)90250-X
- FARGION S, 1992, HEPATOLOGY, V15, P655, DOI 10.1002/hep.1840150417
- Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399
- Hellerbrand C, 2003, CLIN GASTROENTEROL H, V1, P279, DOI 10.1016/S1542-3565(03)00132-0
- Hohler T, 2000, LIVER, V20, P482, DOI 10.1034/j.1600-0676.2000.020006482.x
- Kazemi-Shirazi L, 1999, GASTROENTEROLOGY, V116, P127, DOI 10.1016/S0016-5085(99)70236-2
- Lok CY, 2009, BLOOD, V114, P20, DOI 10.1182/blood-2009-01-199109
- Martinelli ALC, 1999, ACTA HAEMATOL-BASEL, V102, P152, DOI 10.1159/000040991
- Merryweather-Clarke AT, 2000, GENET TEST, V4, P183, DOI 10.1089/10906570050114902
- Mura C, 1999, BLOOD, V93, P2502
- Nahon P, 2008, GASTROENTEROLOGY, V134, P102, DOI 10.1053/j.gastro.2007.10.038
- Porto G, 1998, IMMUNOGENETICS, V47, P404, DOI 10.1007/s002510050376
- Porto G, 2000, HEMOCHROMATOSIS: GENETICS, PATHOPHYSIOLOGY, DIAGNOSIS AND TREATMENT, P51
- Racchi O, 1999, BLOOD CELL MOL DIS, V25, P350, DOI 10.1006/bcmd.1999.0263
- SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
- Santos PCJL, 2010, BRAZ J MED BIOL RES, V43, P107, DOI 10.1590/S0100-879X2009007500031
- SCIOT R, 1989, LIVER, V9, P52
- SIMON M, 1976, GUT, V17, P332, DOI 10.1136/gut.17.5.332
- Smith BC, 1998, HEPATOLOGY, V27, P1695, DOI 10.1002/hep.510270631
- Torres FR, 2008, GENET MOL RES, V7, P60, DOI 10.4238/vol7-1gmr408
- Trifa AP, 2012, J GASTROINTEST LIVER, V21, P177
- UDALOVA IA, 1993, GENOMICS, V16, P180, DOI 10.1006/geno.1993.1156
- Wain HM, 2000, AM J MED GENET, V93, P77, DOI 10.1002/1096-8628(20000703)93:1<77::AID-AJMG14>3.0.CO;2-A